Cipla Q2 PAT may dip 6.7% YoY to Rs. 390 cr: HDFC Securities

HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Cipla to report net profit at Rs. 390 crore down 6.7% year-on-year (down 12.7% quarter-on-quarter).

Net Sales are expected to increase by 8.8 percent Y-o-Y (up 12.7 percent Q-o-Q) to Rs. 4,440 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 5.1 percent Y-o-Y (up 16.4 percent Q-o-Q) to Rs. 850 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.